Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

879 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Beta-amyloid peptides in cerebrospinal fluid of patients with Creutzfeldt-Jakob disease.
Wiltfang J, Esselmann H, Smirnov A, Bibl M, Cepek L, Steinacker P, Mollenhauer B, Buerger K, Hampel H, Paul S, Neumann M, Maler M, Zerr I, Kornhuber J, Kretzschmar HA, Poser S, Otto M. Wiltfang J, et al. Among authors: hampel h. Ann Neurol. 2003 Aug;54(2):263-7. doi: 10.1002/ana.10661. Ann Neurol. 2003. PMID: 12891683
Differential diagnosis of Alzheimer disease with cerebrospinal fluid levels of tau protein phosphorylated at threonine 231.
Buerger K, Zinkowski R, Teipel SJ, Tapiola T, Arai H, Blennow K, Andreasen N, Hofmann-Kiefer K, DeBernardis J, Kerkman D, McCulloch C, Kohnken R, Padberg F, Pirttilä T, Schapiro MB, Rapoport SI, Möller HJ, Davies P, Hampel H. Buerger K, et al. Among authors: hampel h. Arch Neurol. 2002 Aug;59(8):1267-72. doi: 10.1001/archneur.59.8.1267. Arch Neurol. 2002. PMID: 12164722 Clinical Trial.
Treatment with the selective muscarinic m1 agonist talsaclidine decreases cerebrospinal fluid levels of A beta 42 in patients with Alzheimer's disease.
Hock C, Maddalena A, Raschig A, Müller-Spahn F, Eschweiler G, Hager K, Heuser I, Hampel H, Müller-Thomsen T, Oertel W, Wienrich M, Signorell A, Gonzalez-Agosti C, Nitsch RM. Hock C, et al. Among authors: hampel h. Amyloid. 2003 Mar;10(1):1-6. doi: 10.3109/13506120308995249. Amyloid. 2003. PMID: 12762134 Clinical Trial.
Immunotherapy for Alzheimer's disease.
Dodel RC, Hampel H, Du Y. Dodel RC, et al. Among authors: hampel h. Lancet Neurol. 2003 Apr;2(4):215-20. doi: 10.1016/s1474-4422(03)00349-1. Lancet Neurol. 2003. PMID: 12849209 Review.
Measurement of phosphorylated tau epitopes in the differential diagnosis of Alzheimer disease: a comparative cerebrospinal fluid study.
Hampel H, Buerger K, Zinkowski R, Teipel SJ, Goernitz A, Andreasen N, Sjoegren M, DeBernardis J, Kerkman D, Ishiguro K, Ohno H, Vanmechelen E, Vanderstichele H, McCulloch C, Moller HJ, Davies P, Blennow K. Hampel H, et al. Arch Gen Psychiatry. 2004 Jan;61(1):95-102. doi: 10.1001/archpsyc.61.1.95. Arch Gen Psychiatry. 2004. PMID: 14706948
879 results